Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Revenue (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Revenue data on record, last reported at $53.8 million in Q3 2025.

  • For Q3 2025, Revenue rose 363.65% year-over-year to $53.8 million; the TTM value through Dec 2025 reached $62.4 million, up 48.29%, while the annual FY2025 figure was $62.4 million, 48.29% up from the prior year.
  • Revenue reached $53.8 million in Q3 2025 per TNGX's latest filing, up from $3.2 million in the prior quarter.
  • Across five years, Revenue topped out at $53.8 million in Q3 2025 and bottomed at $3.2 million in Q2 2025.
  • Average Revenue over 5 years is $10.7 million, with a median of $6.4 million recorded in 2022.
  • The widest YoY moves for Revenue: up 363.65% in 2025, down 83.99% in 2025.
  • A 5-year view of Revenue shows it stood at $5.7 million in 2021, then rose by 12.16% to $6.4 million in 2022, then decreased by 15.29% to $5.4 million in 2023, then decreased by 24.19% to $4.1 million in 2024, then soared by 1207.04% to $53.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $53.8 million in Q3 2025, $3.2 million in Q2 2025, and $5.4 million in Q1 2025.